Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Analytical Chemistry>Standard>Pharmaceutical Impurity Reference Standards>Loratadine Impurity
Loratadine Impurity
  • Loratadine Impurity
  • Loratadine Impurity
  • Loratadine Impurity
  • Loratadine Impurity
  • Loratadine Impurity

Loratadine Impurity NEW

Price Get Latest Price
Package 10mg 50mg 100mg
Min. Order: 10mg
Supply Ability: 1000
Update Time: 2025-07-31

Product Details

Product Name: Loratadine Impurity Min. Order: 10mg
Purity: 99%+ HPLC Supply Ability: 1000
Release date: 2025/07/31

Loratadine Impurity 

Article illustration


  • Product Number: L019036
  • English Name: Loratadine Impurity 36
  • English Alias: ethyl 4-(2,8-dichloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)-ylidene)piperidine-1-carboxylate
  • CAS Number: None
  • Molecular Formula: C22H22Cl2N2O2
  • Molecular Weight: 417.33
  • Advantages: Loratadine Impurity 36 is synthesized through advanced processes and strict purification procedures, featuring extremely high purity and excellent stability. The product undergoes multiple precise tests, ensuring its accurate chemical structure. It can provide a reliable standard reference for drug research, development, and quality inspection, effectively reducing experimental errors and enhancing the accuracy and repeatability of data.
  • Applications: It is mainly applied to the fields of impurity research, quality analysis, and control of Loratadine drugs. In the drug research and development stage, it can be used to determine the content of this impurity in drugs and evaluate its potential impact on drug safety and effectiveness. During the quality control of pharmaceutical production, as a key reference substance, it can accurately detect the presence of impurities in products, helping enterprises ensure that drug quality meets relevant domestic and international regulations and standards.
  • Background Description: With the continuous improvement of requirements for drug quality and safety in the pharmaceutical industry, the research on drug impurities is a crucial part of ensuring drug quality. As a drug widely used in anti-allergy treatment, the study of impurities in Loratadine is essential for ensuring medication safety and treatment efficacy. Loratadine Impurity 36, as one of the possible impurities in the drug, in-depth research on it helps to improve the drug quality control system and enhance drug quality.
  • Research Status: Currently, research on Loratadine Impurity 36 is gradually deepening. Researchers are committed to developing more sensitive and efficient detection technologies, such as ultra-high performance liquid chromatography - mass spectrometry, to achieve trace detection and precise quantification of this impurity. Meanwhile, studies on its generation mechanism during drug synthesis, as well as its impact on drug stability and efficacy, are also actively carried out, aiming to provide more comprehensive theoretical support and technical guidance for the research, development, production, and quality control of Loratadine drugs.


  • WhatsAPP: +86 17320513646
    E-mail: anna@molcoo.com


    NOTE!

    We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
    This product is intended for laboratory use only!

    WhatsAPP: +86 17320513646
    E-mail: anna@molcoo.com


    NEW IN STOCK!

    The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery! 



Company Profile Introduction

-

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/10mg
VIP2Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2024-04-09
$/
VIP5Y
RongNa Biotechnology Co.,Ltd
2025-04-29
$0.00/1Kg/Bag
VIP5Y
Sinoway Industrial co., ltd.
2023-06-01
INQUIRY